Compare ACMR & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACMR | PTCT |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 5.5B |
| IPO Year | 2017 | 2006 |
| Metric | ACMR | PTCT |
|---|---|---|
| Price | $46.46 | $68.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 17 |
| Target Price | $50.00 | ★ $79.41 |
| AVG Volume (30 Days) | ★ 1.4M | 997.9K |
| Earning Date | 05-18-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | 1.37 | ★ 7.78 |
| Revenue | $74,643,000.00 | ★ $264,734,000.00 |
| Revenue This Year | $28.48 | N/A |
| Revenue Next Year | $24.01 | $21.65 |
| P/E Ratio | $32.92 | ★ $8.02 |
| Revenue Growth | ★ 104.47 | 36.19 |
| 52 Week Low | $16.82 | $35.95 |
| 52 Week High | $71.65 | $87.50 |
| Indicator | ACMR | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 47.80 |
| Support Level | $36.61 | $57.74 |
| Resistance Level | $54.83 | $79.59 |
| Average True Range (ATR) | 3.75 | 2.89 |
| MACD | -2.63 | -0.16 |
| Stochastic Oscillator | 11.54 | 63.37 |
ACM Research Inc supplies advanced, innovative capital equipment developed for the world-wide semiconductor industry. Fabricators of advanced integrated circuits, or chips, can use its wet-cleaning and other front-end processing tools in numerous steps to improve product yield, even at increasingly advanced process nodes. It has designed these tools for use in fabricating foundry, logic and memory chips, including dynamic random-access memory, or DRAM, and 3D NAND-flash memory chips. The company also develops, manufactures and sells advanced packaging tools to wafer assembly and packaging customers.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.